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In the golden age of pharmaceutical nanocarriers, we are witnessing a maturation
stage of the original concepts and ideas. There is no doubt that nanoformulations are
extremely valuable tools for drug delivery applications; the current challenge is how to
optimize them to ensure that they are safe, effective and scalable, so that they can
be manufactured at an industrial level and advance to clinical use. In this context,
lipid nanoparticles have gained ground, since they are generally regarded as non-
toxic, biocompatible and easy-to-produce formulations. Pharmaceutical applications of
lipid nanocarriers are a burgeoning field for the transport and delivery of a diversity
of therapeutic agents, from biotechnological products to small drug molecules. This
review starts with a brief overview of the characteristics of solid lipid nanoparticles
and discusses the relevancy of performing systematic preformulation studies. The main
applications, as well as the advantages that this type of nanovehicles offers in certain
therapeutic scenarios are discussed. Next, pharmacokinetic aspects are described,
such as routes of administration, absorption after oral administration, distribution in the
organism (including brain penetration) and elimination processes. Safety and toxicity
issues are also addressed. Our work presents an original point of view, addressing the
biopharmaceutical aspects of these nanovehicles by means of descriptive statistics of
the state-of-the-art of solid lipid nanoparticles research. All the presented results, trends,
graphs and discussions are based in a systematic (and reproducible) bibliographic
search that considered only original papers in the subject, covering a 7 years range
(2013-today), a period that accounts for more than 60% of the total number of
publications in the topic in the main bibliographic databases and search engines.
Focus was placed on the therapeutic fields of application, absorption and distribution
processes and current efforts for the translation into the clinical practice of lipid-based
nanoparticles. For this, the currently active clinical trials on lipid nanoparticles were
reviewed, with a brief discussion on what achievements or milestones are still to be
reached, as a way of understanding the reasons for the scarce number of solid lipid
nanoparticles undergoing clinical trials.
Keywords: clinical trials, drug delivery, nanostructured lipid carriers, nanotoxicity, pharmacokinetics,
pharmacodynamics, routes of administration, solid lipid nanoparticles
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INTRODUCTION
For many years, lipid materials that are solid at room temperature
have been used in the pharmaceutical industry for the preparation
of different types of formulations such as emulsions, lotions,
ointments and suppositories, among others (de Blaey and
Polderman, 1980). Due to the high affinity of the lipid-
rich intercellular space of the stratum corneum for this kind
of materials, they have been most commonly used as inert
ingredients in topical medications, but lipids (both solid or liquid
at room temperature) are also regular constituents of other
enteral and parenteral formulations, like soft/hard capsules or
parenteral emulsions (Feeney et al., 2016).
Nanoscience, on the other hand, arose initially from the field
of physics and electronic engineering, to rapidly impact other
scientific areas, such as biology, biochemistry, and medicine,
where the size range of nanoparticles (NPs) has historically been
associated with the so-called colloids (Hauser, 1955). Colloidal
systems are dispersion of particles (very large molecules or
molecule aggregates) of intermediate size between molecules in
solution and particles in coarse suspension, and it has been
almost 100 years since a colloidal size range of 1–1000 nm
was proposed (le Chatelier, 1919), which is still accepted today
(McNaught and Wilkinson, 1997).
Hence, the novelty that NPs brought to the biomedical
and therapeutic fields was not their size, but a radical change
in the prevailing therapeutic paradigm: a designed, tailored,
functional or at least protective system, usually carrying a
drug, that could reach the systemic circulation of the patient
along with the drug. In other words, due to their size,
nanovehicles brought down the classical concept that only drugs
dissolved in biological fluids can be absorbed and/or distributed
through the body.
When back in the 90s Müller et al. (2002) proposed the
term solid lipid nanoparticles (SLN R©), as well as nanostructured
lipid carriers (NLC R©), it seemed like a natural idea: to
combine the advantageous characteristics of NPs (mostly
metallic and polymeric at that time) with those of lipid-based
parenteral emulsions, based on non-toxic and biodegradable
lipid components (Schwarz et al., 1994). These lipid NPs were
promoted as a safer option compared to other nanosystems;
they are constituted of a solid matrix that would allow the
controlled release of the drug, but being more stable (and
certainly cheaper) than phospholipid-based liposomes developed
so far (Martins et al., 2007).
If lipid NPs were up to the expectations, is what remains
to be determined. With that in mind, this review presents
an overview of the investigations regarding SLN and NLC
for drug delivery applications, and a descriptive statistical
analysis of the field from 2013 until today. No size restrictions
have been imposed on the systems considered, and the
nano-classification proposed by the authors is maintained.
Consequently, despite that all the reviewed nanovehicles belong
to the colloidal size range mentioned before, those closer to the
upper limit could be better addressed as microparticles, which
have been in the pharmaceutical market for several years now
(Siepmann and Siepmann, 2006).
Our work presents an original point of view, by addressing
the biopharmaceutical aspects of these nanovehicles by means
of trends and descriptive statistics covering the last 7 years of
research in the field. In gathering and presenting the information,
focus was placed on the therapeutic fields of application,
pharmacokinetic aspects, safety issues, toxicological concerns
and current efforts for the translation into the clinical practice
of lipid-based NPs. We believe it will be a valuable read for
all those researchers interested in knowing what therapeutic
challenges are being addressed through the use of SLN, and what
remains to be done.
Our Bibliographic Search
At present, we are witnessing a huge expansion of scientific
knowledge, with countless work groups researching common
themes, collaboratively or individually, throughout all countries
all over the world. This makes it virtually impossible to
review topics in a comprehensive manner, that is, covering
everything published to date with respect to a given topic.
Limiting the information reviewed is thus imperative, with the
inevitable risk of falling into involuntary biases regarding the
information sampling.
Therefore, in order to perform a search as objective as possible,
the following criteria were set:
• Original publications in English dating from the last 7 years:
this meant excluding from the systematic search the review
articles and limiting the search to original works published
since 2013, inclusive. Although it is true that there is a lot of
information prior to that date, the analysis of year-by-year
statistics of academic databases and search engines reveals
that, of the total number of publications retrieved when
searching for the phrase “solid lipid nanoparticles” in the
title, more than 60% correspond to the period 2013-2020. In
particular, publications from 2013 to date were 1600 out of
2630 in Google Scholar (60.8%), 944 out of 1264 in PubMed
(74.7%), and 1300 out of 2111 in Scopus (61.6%), which is
remarkable considering that the total SLN/NLC publication
period is 25 years [the first references date from Maaßen
et al. (1993); Muller et al. (1993)].
• R&D publications focused on the application of lipid
nanosystems for the delivery of drugs, excluding merely
technological developments without any biological or
biorelevant assay. For this, the following keywords
were included in the search (with the “OR” connector):
drug delivery, in vivo, cell, cells, pharmacokinetic,
pharmacokinetics.
Despite Google Scholar retrieved the largest number of
publications, Scopus was selected to perform the final search
due to its more versatile advanced search interface, and the
possibility to download the search results. At the time of
the writing of this work, this search yielded 371 scientific
articles, which constitute the database on which the descriptive
statistics and trends presented in the following sections
are based.
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The Tiny Big Universe of Lipid
Nanoparticles
When firstly developed, SLN were presented as tiny and spherical
particles, made of solid lipids at room temperature, that may be
thought as perfect crystal lipid matrices, able to accommodate
a drug or other molecules between fatty acid chains (Puri et al.,
2009). Nowadays, however, it is known that this is not necessarily
true in all cases, since disc-like shape or flat ellipsoidal geometry
have also been described (Mazuryk et al., 2016; Shah et al., 2019).
Moreover, the loaded drug may be attached mostly to the carrier
matrix surface instead of being embedded into the solid core
(Pink et al., 2019; Shah et al., 2019).
Almost 10 years after SLN introduction, a second generation
of lipid NPs, the nanostructured lipid carriers (NLC) appeared
(Muller et al., 2002). Considered as an advanced version of
SLN, NLC incorporate into their structure small amounts of
liquid lipids at room temperature (oils), to produce structural
rearrangements of the matrix. By that time, it was observed that
the maturation of the crystalline structure that SLN exhibit along
the time often results in the expulsion of the incorporated drug
to the surrounding medium (Mehnert and Mäder, 2001). The
oils in NLC act by reducing the crystalline degree of the lipid
core of SLN, thus avoiding the expulsion of the drug from the
matrix and increasing the drug loading capacity and physical and
chemical long-term stability (Müller et al., 2002). The highly-
ordered crystalline structure of the lipids in a SLN has been
recently studied by Pink et al. (2019) whose work provides a
detailed description of the internal and external structure of SLN.
A detailed description of the materials and methods used for
the synthesis of SLN / NLC is beyond the scope of this review,
and can be found elsewhere (see, for example, Geszke-Moritz and
Moritz, 2016; Gordillo-Galeano and Mora-Huertas, 2018; Jain
and Thareja, 2020). However, it is worth highlighting that, being
strongly hydrophobic, lipidic NPs in aqueous environments
are very low hydrated or no hydrated at all, and thus they
are not able to be spontaneously dissolved or dispersed in
water. Therefore, the preparation of these dispersions necessarily
implies transferring energy to the system, in order to generate
very small particles, with very high specific surface area (Troy,
2000). Regardless the details of each synthesis method, they all
share the common feature of an energy-providing step, under the
form of ultrasonic waves [probe-type sonication (Haque et al.,
2018; Pandya et al., 2018; Scioli Montoto et al., 2018) or ultrasonic
bath (Rajpoot and Jain, 2018; Rosière et al., 2018; Chirio et al.,
2019), high pressures (de Jesus et al., 2013; Küçüktürkmen and
Bozkır, 2018; Wang et al., 2018), high speed homogenization
(Nakhlband et al., 2018; Sathya et al., 2018; Youssef et al.,
2018), or even microwaves (Shah et al., 2016a)]. The comparative
performance of the two most commonly applied methods for
lipid NPs preparation, hot homogenization and high pressure
homogenization, was evaluated in the first studies within the field
(Schwarz et al., 1994).
On the other hand, besides the energy that must be transferred
to the system to create the particles, it is also necessary to
implement other technological strategies in order to maintain
the large surface area exposed by the dispersed NPs. Suspended
in aqueous media, lipid NPs constitute a lyophobic dispersion
(i.e., NPs have no affinity for the dispersing medium), and thus
intrinsically unstable. The most stable state of the lyophobic
colloids contains the dispersed phase aggregated in large
crystals or droplets, to minimize the specific surface area and,
hence, the interfacial free energy (Leite and Ribeiro, 2012).
To prevent this aggregation process (coalescence), the particles
must be electrostatically and/or sterically stabilized (Keck et al.,
2014; Kovačević et al., 2014). Figure 1 shows a schematic
representation of a SLN and a NLC sterically stabilized with a
neutral surfactant.
The superficial charge of lipid NPs is mostly determined by the
materials used for their synthesis, and the pH of the surrounding
medium. The Z potential (ζ) is the electric potential at the
slipping (or shear) plane, i.e., the potential difference between
the stationary double layer of fluid that surrounds a colloidal
particle in suspension and any point in the surrounding liquid
medium. It is a measure of the surface charge of the particle, and
thus it is directly related to the charge exhibited by the lipid or
surfactant of the nanosystem, at the pH value of the formulation
(Cheng and Lee, 2016).
The ζ required to stabilize the lipid NPs dispersion only
by electrostatic repulsion is usually accepted to be ±30 mV
or higher, to assure enough repulsion of nearby NPs in the
suspension (Kovačević et al., 2014). Negative values of ζ are
achieved when particles are formulated with negatively charged
components at the pH of the formulation, like stearic acid
(Liu et al., 2017), sodium taurocholate (Rosière et al., 2018)
or 1-Oleoyl-glycero-3-phosphate sodium salt (Abd-Rabou et al.,
2018), among others. On the contrary, positively charged
starting materials are needed to produce lipid NPs with ζ
values greater than zero, such as stearylamine (Costa et al.,
2018), quaternary ammonium lipids (Doktorovova et al., 2018;
Küçüktürkmen and Bozkır, 2018; Wu et al., 2018) or chitosan
coatings (Liu et al., 2017; Vijayakumar et al., 2017). Nevertheless,
the majority of lipid components (as well as surfactants)
currently used to formulate SLN/NLC are neutral, with the
two most common being ester (e.g., glycerides) and ether (e.g.,
Tween, Poloxamer, Brij) functions. Lipid NPs based on these
materials tend to present ζ values slightly or moderately negative
(between -30 and -3 mV).
The small absolute values of ζ are not enough to prevent
the coalescence of the NPs, which need to be further stabilized
by steric repulsion. To do so, hydrophilic polymers and/or
surfactants are included in the formulation. These compounds
tend to adsorb onto the particles surface and project their polar
residues to the surrounding aqueous medium, thus preventing
the NPs to get too close so that the attractive forces predominate
(Luo et al., 2015).
It is not easy, however, predicting the effect that the NPs
composition and preparation method will have on the ζ,
particle size (PS) and entrapment efficiency (%EE). Systematic
approaches like the quality by design (QbD) concepts, strongly
related to the pharmaceutical industry, are very useful to
comprehensively study and characterize the design space of the
formulation. From the 371 articles reviewed, only 48 (nearly 13%)
applied this type of analysis.
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FIGURE 1 | Schematic representation of a SLN and a NLC sterically stabilized with a neutral surfactant (gray). The oxygen atoms in the liquid and solid lipids are
shown in orange. Drug molecules are not depicted since they may be located inside the lipid core and/or attached to the outer shell.
In terms of the product, QbD tools arise from the recognition
that in order to guarantee the quality, it is not enough (nor
economically efficient) to verify it in the finished product but
has to be incorporated from its design. In the nanotechnology
area, and more precisely, the development and preparation
of SLN/NLC, this idea means to replace the old development
empirical approach (i.e., in an artisanal way) by a more systematic
one, based on the experimental design and the statistical analysis
of the results (ICH, 2009).
To do so, it is usually convenient to start with fractional
factorial designs, which allow to study multiple variables at the
same time with the smallest number of runs: while a full factorial
design requires 2k experiments or runs to study the effect of k
factor at 2 levels (without replicates), the 14 fraction of this design
allows estimating main effects with 2k−2 runs. The decrease in the
number of runs (i.e., in degrees of freedom), inevitably implies a
loss of information, but fractional designs are ideal preliminary
designs, to study several factors at a time with focus on their main
effects, as generally happens during the design of products and
processes (Montgomery, 2017).
Once the more relevant factors are identified, a minor
number of them are studied with more details [i.e., more
levels, so that the “curvature” in the response function can
be addressed) in the optimization stage. For this, response
surface methodologies (RSM) are usually employed (although
other statistical techniques may apply, see for example (Amasya
et al., 2019)]. RSM are generated from designs where factors
are studied in more than two level (n levels), such as full
factorial (nk) designs or more efficient ones like the central
composite or Box-Behnken designs. This type of designs allows
to find functional relationships among studied responses (quality
attributes, such as particle size or ζ) and factors, like the amount
of lipid, the synthesis time or temperature, among others.
The above mentioned is particularly relevant in SLN/NLC
area, since even with the experience accumulated in these years,
very few trends are predictable. Perhaps the only example
is the positive relationship between the amount of lipid and
the particle size, which is verified in almost all the cases
and independently of the drug and preparation method: all
the review articles that include the study of particle size as
a function of the lipid amount found a direct relationship
between them, at least in part of the studied range, if not
in all. However, these results must be interpreted carefully
since the existence of interactions among factors can cause
this relationship to be modified according to the levels of
the other factors. It is not unusual that at higher surfactant
concentrations, the effect of the amount of lipid over the
particle size is minor or null (Cacicedo et al., 2019; Rajpoot
and Jain, 2019). The presence of interactions among factors and
their magnitude can only be studied by means of designs of
several crossed factors, such as those mentioned before, being
insufficient the individual or univariate optimization of the
responses in function of each process attribute or parameter
(Montgomery, 2017).
Systematization of the preformulation stage through the
aforementioned statistical tools allow not only to gain insights
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in a more efficient manner but also to study several response
variables at once. As said before, decreasing the amount of lipid
incorporated into the formulation frequently helps to reduce
particle size, but has a negative effect on the entrapment efficiency
(Kurakula et al., 2016; Talluri et al., 2017; Ahmad et al., 2019).
Simultaneous optimization of both responses as a function of
the formulation components and/or process operational variables
allows to find the optimum compromise solution as well as other
possible approaches, such as increasing the energy (frequency,
speed) during the synthesis to decrease the particle size without
sacrificing entrapment efficiency (Nooli et al., 2017; Dara et al.,
2019; Khatri et al., 2019; Patel et al., 2019a), or decreasing the
surfactant/lipid ratio (Bhalekar et al., 2017; Pandya et al., 2018;
Ahmad et al., 2019).
A DESCRIPTIVE ANALYSIS OF
THERAPEUTIC APPLICATION FIELDS OF
SLN
Figure 2 shows the distribution of publications on SLN/NLC
of the last 7 years, grouped by therapeutic fields. It can be
seen that, as for other nanosystems, cancer treatment represents
the most relevant field of application (Hare et al., 2017). Of
the 371 publications surveyed, 41.8% (155) corresponded to
anticancer therapies, 14.3% (53) to antimicrobials, 12.4% (46) to
the treatment of central nervous system (CNS) diseases and/or
disorders (excluding cancer and infection), 7.3% (27) to site-
specific treatments, 7.5% (28) to nanovehicles not intended for
any specific therapeutic area (i.e., with no indication, including
SLN for diagnostic purposes) and the remaining 16.7% (62)
comprises drugs for various conditions or diseases (in gray
in Figure 2).
In general, the treatment of any disease can be enhanced by
the formulation of drugs loaded into lipid-based NPs, mainly
due to physicochemical and/or biopharmaceutical aspects, like an
improved pharmacokinetic profile, as we will discuss in the next
section. However, the distribution displayed in Figure 2 suggests
that lipid-based NPs may possess additional advantages in certain
specific therapeutic fields.
The large efforts in nanotechnologies focusing on cancer
treatment is not surprising. Cancer is one of the major
public health concerns and is among the leading causes of
death worldwide. According to the National Cancer Institute
FIGURE 2 | Distribution of the 2013–2020 reviewed publications on SLN/NLC, by therapeutic field: anticancer therapies (41.8%, light blue); antimicrobials (14.3%,
pink); CNS diseases, excluding cancer and infection (12.4%, green); site-specific treatments (7.3%, dark blue); various indications (16.7%, gray) and; nanovehicles
not intended for any specific therapeutic area (7.5%, yellow).
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(NCI, NIH), while in 2012 there were 14.1 million new cases
(and 8.2 million cancer-related deaths worldwide), it is expected
that the number of new cancer cases per year will reach
23.6 million by 20301.
The analysis of the database entries corresponding to
SLN/NLC for cancer treatment reveals a great variety of
encapsulated drugs, from large lipophilic molecules such
as taxanes, to small molecules of higher polarity such as
5-fluorouracil. Even Pt-based chemotherapeutic agents (like
the water-soluble drugs cisplatin and oxaliplatin) have been
efficiently loaded into SLN, highlighting the versatility of
these nanocarriers to encapsulate almost the whole range of
chemotherapeutic agents available today.
In addition to the strong reasons for seeking new strategies for
cancer therapies, cancerous tissues possess unique characteristics
that make the choice of nano-based drug delivery especially
interesting. The high rate of tumor growth leads to abnormal
angiogenesis, with abundant fenestrations and large gaps between
endothelial cells, as well as deficient lymphatic drainage in the
area (von Roemeling et al., 2017). Combined, these characteristics
lead to the accumulation, only based on the size (i.e., passive
targeting), of NPs in the tumor vicinity, a phenomenon known as
the Enhanced Permeability and Retention (EPR) effect. Although
there is still controversy regarding the lack of uniformity in the
observed EPR effect between species, at least in some human
tumors the passive targeting of macromolecules and NPs has been
demonstrated (Bjö et al., 2017).
On the other hand, a large number of genes (including
many cell surface and nuclear receptors genes) are amplified
or overexpressed in cancer cells. With the right surface ligands,
NPs may be directed (i.e., actively targeted) to specifically bound
those receptors (Shi et al., 2017). Among the 155 articles of SLN
applicable to cancer, 23 of them involved some active targeting
strategy. In contrast to the wide variety of payloads mentioned
above, the targeting moieties belong, in the majority of cases,
to one of two main classes: peptides and proteins (including
antibodies, 70%) or folate residues (26%).
The α-isoform of the folate receptor, which is normally
expressed at the apical surface of epithelial tissues and
overexpressed in tumor cells of epithelial origin. Hence,
it could be used to promote drug uptake by cancer cells
via receptor-mediated endocytosis, by attaching folate
residues to a nanoparticle surface (Holm and Hansen,
2020). Indeed, this strategy was successfully applied to the
design and preparation of folate-grafted SLN loaded with
irinotecan (Rajpoot and Jain, 2020) and a combination of
resveratrol and ferulic acid (Senthil Kumar et al., 2020)
for the treatment of colorectal cancer. Another example is
found in integrin αvβ3, an adhesion molecule presented
in all cells but overexpressed in several types of tumors. It
has been demonstrated that its interaction with the RGD
tripeptide (arginine-glycine-aspartic) leads to a number of
cell functions that ultimately contributes to angiogenesis
and metastasis (Martínez-Jothar et al., 2020). Conjugation
of SLN with RGD increased in vitro antitumor efficacy and
1www.cancer.gov
in vivo cytotoxicity in comparison with non-targeted SLN
(Zheng et al., 2019).
On the other hand, targeting ligands may be intended to
promote the passage through physiological barriers like the blood
brain barrier (BBB), to reach a site of action at CNS. This
approach was applied in the formulation of docetaxel-loaded SLN
functionalized with angiopep-2 (A-SLN), that specially binds to
the low-density lipoprotein receptor related protein 1 (LRP1)
overexpressed at the BBB. Higher in vitro cytotoxicity and BBB
permeability were found for A-SLN, attributable to receptor-
mediated endocytic processes (Kadari et al., 2018). Moreover,
dual-approaches or combinations are also possible: Kuo and
Lee (2016) achieved an increased toxicity on tumor cells by
incorporating two antibodies for a two-stage targeting: first to
BBB cells (83-14 MAb), and then to glioblastoma cells (AEGFR).
It is worth highlighting that, in order to efficiently conjugate
the targeting moiety to the SLN, much more complicated
synthesis methods are required. The systems are no longer made
of the simple mix lipid/s - surfactant/s - drug/s. Instead, other
reagents, solvents and reaction steps must be incorporated to the
preparation protocol.
There are several options for attaching a targeting ligand to
an SLN, such as linking a fatty acid of the NP with an amino
group of the ligand (Siddhartha et al., 2018), an amino group
of a phospholipid to an acid group of the ligand (Rajpoot and
Jain, 2020), or an amino group of the chitosan coating with an
acid group of the ligand (Senthil Kumar et al., 2020), among
others. Regardless of the particulars, these examples end in the
formation of an amide, which is by far the most widely used bond
to attach ligands to the surface of lipid nanoparticles. In order to
efficiently form an amide bond, activating reagents are required
(carbodiimide, H-hydroxysuccinimide, etc.), and several steps
must be performed in potentially toxic organic solvents.
Therefore, the improvement in efficacy and/or biodistribution
aimed by means of active targeting strategies is achieved by
sacrificing what is (possibly) the main advantage of SLN/NLC:
their green synthesis and safety profile.
Perhaps a better option is to use other types of chemical
bonds instead of covalent bonds. Souto et al. (2019)
synthesized extremely positive SLNs (ca. +70 mV, by choosing
cetyltrimethylammonium bromide as surfactant) able to
electrostatically interact with negatively charged streptavidin
(pI = 5). The objective was to bind a biotinylated antibody
(CAB51, against human epithelial growth receptor 2, HER2),
taking advantage of the strong interaction between streptavidin
and biotin. The goal was somehow accomplished, since in vitro
assays revealed an improved internalization of the targeted
NPs on a HER2 positive cell line (BT-474) compared to a
HER2 negative cell line (MCF-7). But further optimization
will be necessary to reduce the cytotoxicity exhibited by the
nanoparticles themselves, which according to the authors was
probably due to the cationic surfactant and/or their positive
charge (Souto et al., 2019).
Last, but not least, the economic aspect must be mentioned.
The costs of taking a novel nanomedicine into the clinic can be a
significant obstacle for the introduction of new nanomedicines in
the pharmaceutical market (Hare et al., 2017). Histories of success
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like Abraxane, with sales of nearly $1 billion by 2015 (van der
Meel et al., 2017), and efforts like the Cancer Moonshot Task
Force recommendation to enhance public–private partnerships
(Jaffee et al., 2017) are expected to encourage drug developers to
invest time and resources for cancer R&D.
Another area that could take much advantage from
pharmaceutical nanovehicles is the one related to antibacterials,
antivirals, antiparasitic and antifungals, grouped as
antimicrobials in Figure 2.
All the reviewed articles corresponding to SLN/NLC
applications to antiviral therapies present as main advantage the
optimization of the distribution / accumulation of the drug in
the site of action, as well as an improved biodistribution and
diminished cytotoxicity.
As we will discuss later, drugs whose site of action is at the
CNS level always represent a challenge in terms of biodistribution
in order to achieve effective concentrations in the brain. Lipid
NPs of zidovudine and saquinavir intended for the CNS showed
promising results in cell cultures in vitro (Kuo and Wang,
2014; Joshy et al., 2016), and SLN-based formulations of efavirez
(Gupta et al., 2017) and nevirapine (Lahkar and Kumar Das,
2018) exhibited an improved central in vivo bioavailability (BA).
In the case of efavirenz, the strategy was to circumvent the BBB
by means of the nasal administration of the nanoparticles, while
in the nevirapine case the administration was by intravenous
(IV) route and the improved biodistribution was attributed to
the coating (polysorbate 80), able to enrich the protein crown
in ApoE, resulting in a higher passage through the BBB due to
the contribution of receptor-mediated transcytosis (Li et al., 2018;
Krishna et al., 2019).
Regarding antiviral formulations intended for systemic effect
after oral administration (Gaur et al., 2014; Shi et al., 2015;
Ravindra Babu et al., 2019), an interesting work by Ravi et al.
(2014) evaluated the comparative performance of the protease
inhibitor lopinavir (LPV)-SLN with respect to LPV alone and
the combination of LPV-Ritonavir (RTV). LPV is co-formulated
with subtherapeutic doses of Ritonavir to overcome its poor
oral BA due to CYP3A4 metabolism and P-glycoprotein (P-gp)
efflux, both inhibited by RTV. The LPV-SLN presented greater
oral BA than the LPV-RTV combination, and in vitro metabolic
stability and rat everted gut sac studies allowed the authors to
conclude that the observed results were due to a combination of a
metabolic protection and increased intestinal permeability of the
drug encapsulated into the SLN (Ravi et al., 2014).
A very promising aspect, although not still fully addressed,
of the use of lipid-based NP to the delivery of antibiotics is the
possibility to overcome some of the drug resistance mechanisms
acquired by bacteria. Multiple-drug resistance (MDR) may
be acquired by either a mutation or the acquisition of new
genetic material from an exogenous source, that results in a
mutated version of a drug target, membrane protein, transporters
or enzymes, as beta-lactamases. In the same manner as NPs
may help to optimize the pharmacokinetic (PK) profile of
a drug by reducing its metabolism and/or efflux by ABC
transporters in humans, it is feasible to apply the same concept
to overcome the resistance produced by similar mechanisms
in bacteria (Christaki et al., 2020). The possibility to deliver
biotechnological drugs encapsulated into SLN/NLC may also
help to overcome MDR by exploring new therapeutic strategies,
like interfering with the bacterial transcription process through
the delivery of DNA molecules complexed with lipid NP
(González-Paredes et al., 2019).
Moreover, lipid-based nanosystems offer several indirect-
ways to address drug-resistance issues, by one or more of the
following strategies:
• Achieving a sustained release profile of the drug, to
maintain steady concentrations within its therapeutic
concentration, and thus avoiding suboptimal levels which
can promote resistant microbes selection (Nafee et al., 2014;
Chetoni et al., 2016).
• Lowering the drug toxicity by encapsulation, allowing
higher doses and/or treatment periods (Severino et al.,
2015; Chaves et al., 2018).
• Increasing systemic BA (Chetoni et al., 2016; Banerjee et al.,
2020) and CNS levels (Abdel Hady et al., 2020).
• Allowing pulmonary administration, with less unspecific
distribution (Nafee et al., 2014; Gaspar et al., 2016, 2017;
Maretti et al., 2017; Vieira et al., 2018).
• Promoting accumulation in target cells by means of active
targeting (Maretti et al., 2017; Costa et al., 2018; Vieira et al.,
2018; Hosseini et al., 2019; Banerjee et al., 2020).
• Increasing inhibitory effect (i.e., decreasing MIC) over
bacterial strains (Severino et al., 2015; Pignatello et al., 2017;
Ghaderkhani et al., 2019; Rodenak-Kladniew et al., 2019).
On the other hand, the very lipophilic groups of antiparasitic
and azole antifungal agents highlight another advantageous
aspect of lipid-based NPs. Due to its lipid components, SLN/NLC
are able to solubilize highly lipophilic (i.e., aqueous insoluble)
drugs, and keep them in a stable suspension, avoiding the use
of large amounts of surface-active compounds and improving
the biopharmaceutical performance after oral (Souza et al.,
2014; Aljaeid and Hosny, 2016; Omwoyo et al., 2016; Rehman
et al., 2018), ocular (Mohanty et al., 2015; Kumar and Sinha,
2016), and/or parenteral administration (Ahmadnia et al., 2013;
Permana et al., 2019).
The hydrophobic constituents of lipid-based nanosystems
provide a suitable environment for the entrapment of
hydrophobic drugs, positioning SLN/NLC as a promising
tool, particularly relevant in the current context where there
is a growing trend toward more lipophilic drug candidates.
In silico drug discovery strategies, high throughput screening
methodologies and the more classical lead-optimization
programs tend to favor compounds with higher pharmacological
potency, in detriment of other properties that may be desirable
from a physicochemical or pharmacokinetic point of view. On
the contrary, it is a known fact that when the biopharmaceutical
characteristics of drug candidates are addressed in early stages
of discovery programs the consequence is an increase in failures
due to lack of efficacy and, to a lesser extent, for toxicity
concerns (Kola and Landis, 2004). Therefore, pharmaceutical
chemists will always have to deal with the PK/PD & toxicity
balance, and the aqueous solubility will remain to be a
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critical factor in drug discovery. Proof of this is that, to date,
approximately 39% of the marketed drugs (Benet, 2013) and
60% of the new chemical entities (Kovačević, 2020) belong to
the biopharmaceutical categories that group low solubility drugs
(i.e., BCS classes 2 and 4).
ROUTES OF ADMINISTRATION
PROPOSED FOR SLN /NLC
As can be seen in Figure 3, the most commonly proposed
administration route for lipid-based nanosystems is the
parenteral route, closely followed by the oral route. Both
administration routes seek to achieve systemic effects of the
encapsulated drugs, but the trend described is opposite to the
current distribution of pharmaceutical products in the market,
where the oral route of administration is the preferred and most
widely used route for drug administration.
Parenteral routes, on the other hand, allow the delivery of
drugs directly to the systemic circulation with no absorptive
barriers to overcome or with minimal restrictions, as in the
case of the intramuscular and/or subcutaneous route. More
than 50% of the lipid nanosystems assayed by parenteral
routes (46 out of 81) corresponds to anticancer drugs, a
therapeutic field where IV route remains predominant, in spite
of its non-negligible negative aspects, such as invasiveness,
associated risks, inability to self-manage and higher technological
requirements to be manufactured with suitable microbiological
quality (Ruiz and Scioli Montoto, 2018).
Oral Route
The oral route, being a natural route of entry of substances to
the organism, enjoys the greatest acceptability, as well as some
technological advantages, since oral pharmaceuticals mostly
comprise non-sterile solids dosage forms. For a successful therapy
by the oral route, though, a drug must generally fall within certain
ranges of lipophilicity, molecular weight, and hydrogen bonding
ability, as well as aqueous solubility and permeability, which
altogether contribute to its druglikeness (Di and Kerns, 2016).
Curcumin, for example, represents a real challenge for its
formulation as oral product, due to its very low aqueous
solubility, poor absorption, rapid metabolism and pH-dependent
degradation rate (Sanidad et al., 2019). Oral BA of curcumin has
been reported to be as low as 1% (Ma et al., 2019). On the other
hand, successful outcomes of curcumin in both preclinical and
clinical trial of different diseases make it a very promising drug,
that seems to be able to modulate several cell signaling pathways
and, thus, holds a great therapeutic potential against a wide
range of human diseases (e.g., cancer, infections, inflammatory,
metabolic and neurodegenerative diseases, among others) (Gupta
et al., 2013). Furthermore, there is enough evidence to support
the hypothesis of dose-dependent pharmacological activity of
curcumin, with the anticancer properties corresponding to the
highest doses (Doktorovova et al., 2018).
FIGURE 3 | Distribution of the 2013–2020 reviewed publications on SLN/NLC, by the proposed route of administration. Only publications with a PD and/or PK
studies were considered (211 of 371).
Frontiers in Molecular Biosciences | www.frontiersin.org 8 October 2020 | Volume 7 | Article 587997
fmolb-07-587997 October 25, 2020 Time: 16:20 # 9
Scioli Montoto et al. SLN for Drug Delivery
Regardless the somehow inconsistent reports on curcumin
oral BA (possible due to variations in experimental conditions),
there is agreement on the positive increment in the oral BA
of curcumin formulated within nanosystems, with respect to
the free drug in solution (Anand et al., 2007). Predictably, the
publications reviewed here confirmed that trend, since curcumin
oral BA achieved with SLN/NLC was from 2 to more than 10-
fold higher than that of the free drug solution (Kakkar et al.,
2013; Ramalingam and Ko, 2015; Baek and Cho, 2017). The
examination of the PK profiles seems to indicate that the BA
improvement of curcumin is related to the combined effect of a
higher absorption and a minor elimination of the encapsulated
drug, similarly to what was described for LPV-SLN.
Among the reviewed articles, the aforementioned trend is
confirmed by many other examples. Administration as SLN/NLC
greatly increases the oral BA of drugs with very low aqueous
solubility such as aripiprazole (Silki and Sinha, 2018), rhein (Feng
et al., 2017), zaleplon (Dudhipala and Janga, 2017), miconazole
(Aljaeid and Hosny, 2016), raloxifene (Singh et al., 2013; Tran
et al., 2014), efavirenz (Gaur et al., 2014), doxorubicin (Yuan
et al., 2013), asenapine (Patel et al., 2019b), linagliptin (Veni
and Gupta, 2020), and niclosamide (Rehman et al., 2018),
among several others.
The group of calcium channel blockers derived from
dihydropyridine, for example, is characterized by its low oral
BA due to its low water solubility and high rate of first-
pass metabolism. Administered as lipid-based nanosystems,
significant increases in the oral relative BA was observed for
isradipine [4.5-fold, (Kumar et al., 2018)], nisolpine [2.5-fold,
(Dudhipala et al., 2018)], felodipine [3.2-fold, (He et al., 2020)],
and cilnidipine [2.4-folds, (Diwan et al., 2020)]. These are
very promising results taking into consideration that, when
administered as conventional formulations, the oral BA of these
four drugs is in the range of 5-20% (Wishart et al., 2018).
These previous examples illustrate the possibilities and
advantages offered by lipid NPs for oral pharmacological therapy.
Nonetheless, despite the abundance of PK and pharmacological
“advantages,” the underlying mechanisms are not yet fully
understood. Regarding the higher oral BA, evidences suggest a
combination of four possible effects:
(1) Drug protection against both chemical and enzymatic
degradation. Encapsulation in a nano-sized lipid matrix
may reduce or retard a drug pH-dependent hydrolytic
degradation (Baek and Cho, 2017), as well as the drug
inactivation by the gastrointestinal (GI) tract digestive
enzymes, which may be crucial for the oral administration
of biological drugs. It has been demonstrated, for
example, that whereas free salmon calcitonin was almost
completely degraded in vitro by pancreatin in 15 min,
the drug encapsulated into SLN exhibited a much slower
degradation kinetics, and was still detectable in the reaction
media up to 12 h (Fan et al., 2014).
(2) Lipid effect on solubility improvement that allows higher
effective doses. Shangguan et al. (2015) evaluated the BA of
silymarin in Beagle dogs, comparing the administration as
intact drug-loaded SLN/NLC and as a lipolysate produced
by the enzymatic action of pancreatic lipase over the lipid
NP. The lower BA obtained with the lipolysate was in
agreement with the loss of drug in the formulation, since
the micelles formed in the GI to facilitate the uptake
of lipophilic compounds (known as “mixed micelles,”
and mainly composed by phospholipids, bile salts, and
cholesterol, Yao et al., 2017) cannot keep all silymarin
in suspension, and drug precipitation occurs. In other
words, when the BA values are corrected by a factor
that accounts for the true dose administered (i.e., amount
of drug remaining in suspension), it may be concluded
that the lipolysis pathway is the predominant mechanism
underlying the enhanced oral BA of a drug formulated
as lipid NPs, whereas the absorption of intact NPs only
plays a minor role.
(3) Major retention in the GI tract. When a lipid-based NP
reaches the GI tract, its hydrophobic surface tends to
adhere to the mucus layer, whose superficial layers are
quickly and continuously cleared as protection against
particles and pathogens (Maisel et al., 2015). To minimize
such effect, “mucus penetrating particles” (MPP) can be
formulated. MPP have a smaller size than the mucus layer,
and a hydrophilic, non-muco-adhesive surface (generally
obtained with PEG cover) (Schneider et al., 2017). In spite
of their lipid nature, these particles are capable of getting in
contact with the GI epithelium, thus achieving prolonged
absorption of the encapsulated drug (Yuan et al., 2013).
(4) Finally, in the same way that NPs protect the drug from
degradation by enzymes present in GI lumen, they can
also prevent/reduce the degradation by metabolic enzymes,
as in the lopinavir example mentioned in the previous
section (Ravi et al., 2014). Reduction in pre-systemic in vivo
metabolism may occur due to less hepatic metabolism
(e.g., NP accessing portal circulation as such, see the
next section) and/or increased lymphatic uptake of the
NPs by the lymphatic vessels in the gut (Baek and Cho,
2017; Bernier-Latmani and Petrova, 2017). Working with a
chylomicron production blocking agent, Patel et al. found
that the lymphatic uptake represented nearly 30% of the
drug oral BA (asenapine maleate, administered as a SLN
suspension) (Patel et al., 2019b).
Additionally, we can mention one more effect, common
to all orally administrable pharmaceutical forms: the
presence of excipients that may affect the rate and extent
of drug absorption (FDA/CDER, 2015). Tensioactives and
surfactants belong to this group and are usually present at high
concentrations in SLN/NLC.
It is likely that the combination or synergistic action of all
these effects is the cause of the large increase in oral BA associated
with lipid nanovehicles and, in turn, of the increasing trend
in the selection of this route of administration for SLN/NLC
(see Figure 4). Furthermore, due to all the previously described
effects, lipid-based NP have been examined for the oral delivery of
peptide therapeutics, such as salmon calcitonin (Chen et al., 2013;
Fan et al., 2014) and insulin (Hecq et al., 2016; Xu et al., 2018;
Alsulays et al., 2019).
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FIGURE 4 | Time-trend of the SLN/NLC intended for oral administration. Only publications with in vivo (PD and/or PK) studies are considered (211 of 371).
Percutaneous Route
According to the FDA classification, the percutaneous route
of administration consists in the administration of drugs
through the skin (FDA, 2017), and it comprises two groups of
pharmaceutical products: those intended to exert a local action,
at some level of the skin, and those that seek a systemic action
of the drug, also known as transdermal formulations. Of the
30 reviewed publications corresponding to preparations to be
administered onto the skin, only 3 of them (10%) seek systemic
action of the drug: metformin for diabetes (Sharma et al., 2013),
avanafil for erectile dysfunction (Kurakula et al., 2016) and
piperine for rheumatic arthritis (Bhalekar et al., 2017), while the
remaining 90% consists of formulations for local action.
The skin is composed of two main histological layers, the
epidermis at the surface, and the dermis below. In turn, the
outermost layer of the epidermis is the stratum corneum or the
horny layer, which is the real barrier that prevents the entry
of foreign (and potentially harmful) substances into the body.
The stratum corneum is formed by cells named corneocytes or
keratinized cells, surrounded by shallow valleys that comprise
the intercellular regions filled with lipid multilamellae, rich in
ceramides, fatty acids and cholesterol.
The ability of a drug to penetrate the skin depends on its
physicochemical properties (mainly its size, molecular weight,
pKa and partition coefficient) as well as the vehicle in which
it is formulated. There are substances known as “permeation
enhancers” which are capable of reversibly disorganizing the
stratum corneum, facilitating the drug entry (e.g., fatty acids
and alcohols with long carbon chains, surfactants, terpenes and
fatty esters, Gupta et al., 2019). These excipients are commonly
used in classic semi-solids preparations like emulsions, lotions
and ointments, as well as of their more recent relatives’
lipid-based nanoformulations. Hence, it is logical that these
formulations are, among other nanosystems, the first choice for
percutaneous/transdermal applications.
The most studied nanoparticulate systems for percutaneous
application are, by far, liposomes. And although it has been
shown that the constituent lipids of liposomes are capable of
reaching the deeper layers of the skin (i.e., the dermis), it still
remains unclear if they can act as carriers, penetrating through
the skin, or if they only act as penetration enhancers, changing
the skin physical properties in a way that facilitates the (free) drug
penetration through it (Peralta et al., 2018).
Nevertheless, pharmaceutical formulations of SLN/NLC have
proven to be useful for percutaneous administration of drugs,
to treat diseases or alterations at every level of the skin:
the epidermis, like fungal infections (Vaghasiya et al., 2013),
hyperpigmentation (Ghanbarzadeh et al., 2015), skin cancer
(Taveira et al., 2014; Geetha et al., 2015; Khallaf et al., 2016;
Tupal et al., 2016) and atopic dermatitis (Kang et al., 2019); the
dermis, as in the case of anti-inflammatory drugs (Dasgupta et al.,
2013; Gaur et al., 2013; Raj et al., 2016; Daneshmand et al., 2018;
Shinde et al., 2019) and local anesthetics (You et al., 2017); both
dermis and epidermis, like psoriasis (Sonawane et al., 2014) and
infections by herpes virus (Gide et al., 2013; El-Assal, 2017) and;
the appendices, like hair follicles (Hamishehkar et al., 2016).
DISPOSITION IN THE BODY AND
PENETRATION TO THE CNS
Studying the distribution of these drug delivery nanosystems
within the body is one of the main research challenges in the
field. Although the advances that so far have been achieved in
terms of the development of SLN/NLC are relevant, only a few
works are dedicated to a detailed study of the fate of this type
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of NPs once they enter the organism. This section is intended to
describe the main mechanisms involved in the uptake, transport
and distribution of NPs into the body, as well as how these
structures face the natural barrier that protects the CNS.
Gastrointestinal Absorption of Lipid
Nanoparticles
As mentioned in previous sections, SLN and NLC proved to be
particularly promising for the enhancement of drugs oral BA,
by avoiding their degradation in the GI tract, improving their
solubility and dissolution rate, increasing their contact with the
epithelium and/or minimizing their efflux by P-gp and other drug
transporters. Either by one or by several of these mechanisms,
orally administered lipid NPs can effectively increase the area
under the plasmatic concentration curve of the encapsulated
drug, as described by the curcumin examples. In the same
manner, Wang and co-workers managed to improve the oral BA
of [6]-shogaol, an alkylphenol extracted from ginger roots, of
great interest for its antitumor, antioxidative and antirheumatic
properties, as demonstrated by the greater AUC exhibited by the
drug incorporated into SLN, but also by a significant decrease
of serum uric acid, IL-1β and TNF-α levels with respect to free
[6]-shogaol tests (Wang et al., 2018).
NPs constituents could have an effect on the intestinal
absorption enhancement: lipids are able to increase the intestinal
mucosa permeability (Talegaonkar and Bhattacharyya, 2019) and,
although some controversy exists (Ball et al., 2018), modulation
of the tight junctions (Beguin et al., 2013). On the other hand,
tensioactives, surfactants and hydrophilic coatings like chitosan
have also been proposed to enhance BA by the opening of tight
junctions (Han et al., 2019; McCartney et al., 2019).
Overall, when it comes to the demonstration of the GI
absorption of intact NPs, evidence is much scarcer. Regarding
cellular uptake of the NPs, endocytosis is considered the
predominant pathway (Wang et al., 2011; Patel et al., 2019b).
There are two principal endocytosis mechanisms: pinocytosis
and phagocytosis. Cellular uptake by macrophages (phagocytic
cells) is reserved for those particles larger than 0.5-10 µm
(Zhao et al., 2011). Pinocytosis, on the other hand, occurs in
all types of cells and is responsible of the uptake of smaller
particles (50 nm–5 µm). It may be further classified into
clathrin-dependent (or clathrin-mediated endocytosis, CME)
and clathrin-independent, the latter comprising caveolae-
mediated and clathrin/caveolae-independent endocytosis, and
macropinocytosis (also clathrin/caveolae independent, but for
the internalization of larger particles, similar to phagocytosis)
(Sahay et al., 2010).
This classification is based on the proteins (clathrin and
caveolin) involved in the endocytic process, and thus it may
overlap with other classifications based on different criteria,
like receptor mediated or adsorptive endocytosis. For example,
it was proposed that folate grafted NPs may be internalized by
clathrin-mediated, clathrin/caveolae-independent (Sahay et al.,
2010) and/or caveolae−mediated endocytosis (Wang et al., 2011).
Rajpoot and Jain (2018, 2019) employed folic acid (FA) as
targeting ligand of SLN containing oxaliplatin and irinotecan
for the treatment of colorectal cancer, finding a slightly higher
uptake (and higher toxicity) of the FA-SLN compared with the
non-targeted SLN in HT 29 cells.
Cellular uptake via the LDL receptor, on the other hand,
occurs by CME (Sahay et al., 2010; Wang et al., 2011).
This pathway has been explored for the active targeting of
rosuvastatin loaded SLN (Beg et al., 2017). To mimic the
outer layer of LDL particles, rosuvastatin-SLN were coated with
phospholipids (phospholipon 90G and/or PEGylated DSPE), and
the endocytosis process was studied in Caco-2 cells by using
filipin and sucrose as specific blockers of caveolae and clathrin-
mediated endocytosis, respectively. A significant reduction in the
cellular uptake of the drug in the presence of sucrose was found,
providing indirect evidence of the lipid NPs internalization via
the LDL receptor by CME (Beg et al., 2017). CME was also
the predominant pathway responsible for the internalization of
stearic acid based-SLN in human epithelial cells (lung A549 and
cervical HeLa cells) (Shah et al., 2016b).
It is worth mentioning, however, that the successful
endocytosis of a NP does not guarantee its absorption: once in
the intracellular space of an epithelial cell, the NP should be
further exocytosed on the basolateral side to reach the capillary
vessels, in a process known as transcytosis. A comprehensive
work by Chai et al. (2014) showed that SLN (60-100 nm) with
no targeting ligand were internalized mostly by caveolae and
clathrin-mediated endocytosis in MDCK cells. Once inside the
cells, lysosomes were the main destination of the endocytic
vesicles, whereas the transcytosis to the basolateral side account
for only about 2.5% of the total NPs (Chai et al., 2014). This
result is in line with those of Hu et al. (2016), who concluded that
orally administered SLN exhibit significant cellular uptake but
fail to penetrate cell monolayers. The authors studied the in vivo
distribution of SLN and their interaction with biomembranes by
water-quenching fluorescence, and could not find evidence of
penetration of integral nanocarriers (Hu et al., 2016).
In a follow-up article, however, the same authors found some
evidence of intact uptake of the SLN from the GI lumen to
the circulation, apparently through the lymphatic route, but
representing only a minor contribution to the oral BA of a drug
(Ma et al., 2017). Regarding the lymphatic uptake, lipid NPs may
access the lymphatic system through the intestinal lipid transport
system (O’Driscoll, 2002) as well as by transcellular passage, by
the association with chylomicrons after the digestion of the lipid
nanosystems, and by specific passage through the M-cells in the
Peyer’s patches (Salah et al., 2020). In the last case, NPs size is
a relevant variable, since particles larger than 100 nm will be
retained longer in the Peyer’s patches, while smaller ones will
be transported to the thoracic duct (Bummer, 2004). Surface
charge is also a key feature that affects this process, with anionic
particles being more rapidly absorbed by the lymphatic route
(Yu et al., 2019).
Systemic Circulation and Protein Corona
Formation
Due to their small size and, thus, their large surface area, NPs are
characterized by a high free energy. Accordingly, the interaction
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with different macromolecules, when they are in contact with
biological fluids, will be favored. Once NPs have reached systemic
circulation, another inconvenience is presented: a biological
macromolecules-cover known as protein corona (PC) begins to
form upon their surface.
This corona is composed of two layers formed in a time
dependent manner. During a first stage, a loose layer named
soft corona starts to settle. This corona is composed by low-
affinity proteins with a high relative abundancy, which are in
constant exchange with the biological medium and NPs surface,
in a process known as “Vroman effect” (Vroman, 1962). Then, in
a second stage, low-affinity proteins begin to be replaced by those
with lower relative abundance, but with a higher surface affinity,
staying close to it for a longer period. Is in this stage where the
formation of the hard corona is evidenced (Baimanov et al., 2019).
It follows that the “chemical identity” of the NP is not equal to its
“biological identity:” the formation of the PC (both soft and hard)
substantially changes the nanosystems properties, being able to
impact in their size, shape, and final surface composition (Lima
et al., 2020), turning them into a new biological identity.
Gessner et al. (2002) studied the influence of surface charge
density on protein adsorption on polymeric NPs, concluding that
the higher the surface charge density, the higher the amount of
proteins adsorbed. The authors observed no qualitative change
in the pattern of adsorbed proteins.
As expected in a complex biological process, the pattern of
protein adsorption does not only depend on the protein capacity
to access the particles surface, but also on the characteristics
of the surface itself (Göppert and Müller, 2003). As it was
previously described for polysorbate 80 coatings, the use of
different Poloxamer in the formulation of SLN facilitates the
adsorption of different proteins in vitro: the MW Poloxamer
184 and Poloxamer 235 showed a high ApoE absorption, which
mediates the uptake through the BBB. Even more interesting,
these lipid NPs showed a high adsorption of ApoA-IV (involved
in the promotion of brain uptake) and a low adsorption of ApoC-
II (responsible for the inhibition of receptor mediated binding
and uptake of lipoproteins) (Goppert and Muller, 2005).
During the formation of the PC, the incorporation of proteins
of the complement system also known as opsonins occur. The
complement system is part of the innate immune system and
facilitates the recognition of NPs by the mononuclear phagocytic
system (MPS), which in turn leads to an increase of NPs clearance
and a reduction of their systemic residence time.
A study by Fang et al. (2006) confirmed the dependency
of phagocytosis by murine macrophages with the particle size
of the NPs, as well as with the molecular weight of methoxy
polyethylene glycol (MePEG) used for coating. The authors
observed that those NPs coated with MePEG of the same
molecular weight, showed a higher distribution half- life as the
size decreased. On the other hand, the uptake by macrophages
was decreased by increasing the coating molecular weight
(Fang et al., 2006).
Previously, Müller et al. (1996a) had studied the dependence
of the uptake by macrophages with hydrophilicity and steric
hindrance given by different types of emulsifiers (e.g., poloxamine
908 and poloxamer 407), demonstrating that an increase in
hydrophilicity and steric hindrance diminished the uptake by
macrophages. Xiao et al. (2011) worked with different types of
D-aspartic acids and D-lysines-derivatized telodendrimers which
possessed different surface charges. Those dendrimers composed
by D-aspartic acids (negatively charged) and the acetylated
derivatized NPs (neutral charge) showed a lower macrophage
uptake in comparison with the cationic D-lysines (positively
charged) (Xiao et al., 2011).
To achieve distribution beyond the liver, NPs need to avoid
rapid opsonization and clearance by the MPS (Müller et al.,
1996a). A great deal of work has been devoted to developing
the so-called stealth NPs, which are “invisible” to macrophages
(Brigger et al., 2012; Rudhrabatla et al., 2019, 2020), due to the
PEG chains on their surface (PEGylated NPs) (Hadjesfandiari,
2018). This coating prevents or delays the formation of the
PC and, thus, NPs exhibit a prolonged half-life in the blood
compartment (Pelaz et al., 2015). However, a number of
limitations to the use of PEG have also been described, such as the
production of anti-PEG antibodies or the impairment of cellular
internalization by the stealth coating (Baimanov et al., 2019).
Depending on the nature of the nanovehicle, different approaches
have been explored to circumvent these limitations, e.g., stimuli-
responsive PEG-derivatized nanocarriers (Fang et al., 2017).
Passage Through the Blood Brain Barrier
(BBB)
The BBB is a semipermeable structure composed mainly of
the microvasculature of the CNS. This barrier is formed by a
continuous layer of endothelial cells integrated to a complex
systems that regulates the bloodstream-to-CNS movement of
molecules, ions and cells, also responsible for the homeostasis
regulation (Ayloo and Gu, 2019). Unlike the peripheral
endothelium, BBB endothelial cells present a high content
of mitochondria, lack of fenestrations and pinocytic activity
and, as a salient characteristic, particularly occlusive tight
junctions formed by several transmembrane proteins (such as
claudins, occludins, and junctional adhesion molecules or JAM,
among others Stamatovic et al., 2008), that efficiently limit the
paracellular diffusion pathway. Another characteristic of the BBB
is the expression of efflux transporters of the ABC (ATP-binding
cassette) superfamily, transmembrane proteins responsible for
pumping xenobiotics or toxic substrates out of the intracellular
space, avoiding their access to the CNS since they are localized
almost exclusively at the luminal membrane of the endothelial
cells (Pardridge, 2020). These transporters are one of the main
causes of multi-drug resistance phenomena, which is why they
are also known as multidrug resistance (MDR) proteins (the
most representative one being P-gp). It has been proposed
that encapsulating a drug into a NP may help to bypass these
transporters (Cavaco et al., 2017; Sadegh Malvajerd et al., 2019).
The transport of substances through the BBB may occur by
four main mechanisms (Xie et al., 2019): paracellular diffusion,
reserved for small water soluble substances; transcellular
diffusion, which is more relevant for molecules with an
appreciable lipophilicity and a molecular weight smaller than
450 kDa; carrier-facilitated diffusion and active transport,
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responsible for the passage of specific molecules like small
peptides, sugars, monocarboxylic acids, amino acids, organic
anions and cations, neurotransmitters and nucleosides; and
endocytosis, this pathway has been reported for the passage of
peptides and proteins through the BBB, such as insulin and the
insulin-like growing factor (IGF-I and IGF-II) (Patel et al., 2013).
Although it has been suggested that NPs can enter the CNS
by the paracellular pathway (through the transient opening of
the tight junctions, as in the case of chitosan-coated NPs, Yu
et al., 2013; Zhang et al., 2014), there is now evidence suggesting
that the predominant mechanism is the NPs endocytosis. Once
inside the endothelial cell, NPs can be exocytosed to the other
side (transcytocis of the NP) or released in the intracellular space,
promoting their access to the CNS (Saraiva et al., 2016).
Since endocytosis of NPs by the BBB endothelial cells seems to
be predominantly mediated by receptors, many efforts have been
made with SLN surface functionalization to enhance their CNS
availability (Ceña and Játiva, 2018; Kuo et al., 2019; Wang et al.,
2019), as discussed in Section 2 for the functionalized angiopep-2
NPs to treat glioblastoma multiforme (Kadari et al., 2018).
As another example, functionalized ApoE NPs appear to
be particularly promising in such way. ApoE possess high
affinity receptors along the BBB, a characteristic that has been
exploited for the delivery of drugs in functionalized nanosystems
with this protein (Zensi et al., 2009). In a series of studies,
Neves et al. investigated the cellular uptake of ApoE-grafted
SLN by hCMEC/D3 cells, as a model of human BBB, and
found that functionalized NPs were better internalized than
non-functionalized ones, due to the specific recognition of the
targeting ligand by the highly expressed LDL receptors (Neves
et al., 2015, 2016, 2017). Moreover, by the use of specific
inhibitors, CME was identified as the preferential endocytic
pathway for ApoE-SLN (Neves et al., 2017).
CLEARANCE MECHANISMS AND
TOXICOLOGICAL ASPECTS
Achieving nanocarriers with low or no toxicity for the organism
and the environment is one of the biggest challenges in designing
drug delivery nanosystems. Ideally, the drug carrier should be
rapidly removed from the body after the drug has been released.
Lipid-based NPs sizes are far over the renal filtration threshold
(Yang et al., 2019), for what, once in the bloodstream, they have to
be opsonized by serum proteins and subsequently uptaken by the
MPS in specialized organs (i.e., liver, kidney, spleen, lungs, and
lymph nodes) for their efficient elimination from the body (Di
Ianni et al., 2017). Despite the fact that fenestrations in the spleen
may filter out particles larger than 200 nm, particle deformability
can allow large particles to squeeze through them and remain in
the bloodstream (Park et al., 2017).
Considering the clearance mechanism described above, Keck
and Müller (2013), a “nanotoxicological classification system”
(NCS), as a rational approach to assess the potential risks of
toxicity of a given nanocarrier. According to that system, a
nanocarrier is placed in one of four categories according to their
size and biodegradability (Figure 5):
FIGURE 5 | Nanotoxicological classification system (NCS) suggested by Keck
and Müller (2013). NPs are placed in one of four categories according to their
size and biodegradability: class I (no or low risk), classes II and III (medium
risk), and class IV (high risk).
• Class I (no or low risk), for nanosystems of size above of
100 nm and made of biodegradable materials.
• Class II (medium risk), for nanosystems of size above
100 nm but made of non-biodegradable materials.
• Class III (medium risk), for nanosystems of size below
100 nm, made of biodegradable materials.
• Class IV (high risk), for nanosystems of size below 100 nm
and made of non-biodegradable materials.
The size limit between classes of 100 nm was adopted
considering the greater distribution in the organism of smaller
particles (e.g., ease of access to the CNS), as well as the
greater probability of non-specific endocytosis in off-target cells.
However, when applying the NCS, it should be taken into
consideration that larger particles can also be internalized by the
cells through other mechanisms (Zhao et al., 2011; Danaei et al.,
2018).
With regard to the biodegradability of the nanocarrier
materials, SLN and NLC are generally considered as members
of the NCS classes I or III, since they are composed of
physiologically compatible lipids (fatty acids, glycerides or other
fatty acid esters, sterols, sterol esters, waxes, etc.).
As stated before, a NP in the bloodstream will be taken
up by the MPS. After the opsonization and phagocytosis has
occurred, the resulting phagosome needs to “mature” to a
phagolysosome [by a series of fusion and fission interactions
with endosomes and lysosomes (Rosales and Uribe-Querol,
2017)]. The phagolysosome possesses a unique membrane
composition to resist a very acidic and degradative environment,
necessary to the final digestion of its content. Internalized non-
biodegradable materials may however exert several cytotoxic
effects, contributing to chronic inflammation and progressive
tissue injury (Gordon, 2016; Azarnezhad et al., 2020).
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It must be noted that toxicological outcomes are strongly
dependent on the administration route: for instance, orally
administered SLN/NLC can be eroded and degraded by bile salts
and pancreatic lipase in the body (Müller et al., 1996b; Agrawal
et al., 2014).
Although the previously described classification system may
seem an excessively reductionist approach to the matter of
nanotoxicology, it is a valuable tool in the current state of research
of pharmaceutical nanovehicles. A huge number of different
nanosystems are being proposed for drug delivery applications
based on promising results in terms of their PK and/or PD
performance, but for which the multiple aspects that could
generate adverse events or toxicity in patients are still to be
studied in detail.
One of the aspects not directly addressed by the NCS is
the effect that the surface charge of the particles may exhibit
on the toxicity or clearance mechanisms. In order to enhance
cellular uptake, NPs are sometimes formulated with a positively
charged surface, to facilitate electrostatic interaction with the
negatively charged plasma membranes of cells, hence promoting
internalization by non-selective, adsorptive mediated endocytosis
(Ayloo and Gu, 2019). An example of this strategy is found
in lipoplexes (a combination of negatively charged nucleic
acids and positively charged lipids), which have demonstrated
their ability to effectively deliver their load to target cells
(Kowalski et al., 2019; Pardridge, 2020). Positively charged
lipid NPs were also proposed for carrying nucleic acids (Kong
et al., 2013; Fàbregas et al., 2014; Shi et al., 2014; Kotmakçı
et al., 2017; Küçüktürkmen and Bozkır, 2018; González-Paredes
et al., 2019). Despite these advantages, positively charged NPs
have been associated with several toxic effects (Azarnezhad
et al., 2020). Based on cell cultures experiments, some authors
reported higher cytotoxicity values for cationic (vs. neutral and
anionic) SLN (Karn-orachai et al., 2016), while others postulate
that cell cultures are able to tolerate high concentrations of
cationic SLN/NLC without appreciable toxicity (Doktorovová
et al., 2016). These apparently inconsistent results may be
explained by the fact that surface charge is not the only
toxicity determinant of a NPs, and that other covariables
(such as the chemical composition of the NP) may also
be considered.
Nevertheless, caution should be taken when working with
cationic SLN/NLC, as also some in vivo toxicity reports may
be found. For example, Wu et al. (2018) demonstrated that
SLN with different surface charges and PEG densities resulted
toxic to platelets (and, to a lesser extent, to red blood cells),
and that the toxic effects were dependent of the surface charge
(the higher positive charge, the worst) and PEG densities (the
lower, the worst).
TRANSLATION INTO THE CLINIC OF
LIPID (BUT NOT SOLID)
NANOPARTICLES
At the time of writing this review, a search was made on
the website www.clinicaltrials.gov, finding 13 relevant results
corresponding to the keywords “lipid” and “nanoparticles” (see
Table 1). However, of those studies, only one comprise what can
be regarded as classical SLN: oxiconazole-loaded stearic acid NPs,
further included in a carbopol gel formulation for the topical
treatment of topical tinea infections (Mahmoud et al., 2020).
TABLE 1 | Lipid Nanoparticle Drug Delivery Systems (LNDDS) on currently active clinical trials (terminated or withdrawn studies were excluded).
Track number Status Drug Disease Route of administration
siRNA therapy
NCT01960348 Phase III Patisiran (ALN-TTR02) hTTR - mediated amyloidosis IV infusion
NCT01858935 Phase I ND-L02-s0201 Hepatic fibrosis IV infusion
NCT02227459 Phase I ND-L02-s0201 Hepatic fibrosis IV infusion




NCT04416126 Phase I ARCT-810 OTC deficiency IV infusion
NCT04442347 Phase I ARCT-810 OTC deficiency IV infusion
NCT03323398 Phase I Phase II mRNA-2416 Solid tumors / Lymphoma / Ovarian
Cancer
Intratumoural
NCT03739931 Phase I mRNA-2752 Solid tumor malignancies / Lymphoma Intratumoural
NCT04283461 Phase I mRNA-1273 COVID-19 IM injection
Others
NCT02971007 Phase II CAMB Vulvovaginal candidiasis Oral
NCT02629419 Phase II CAMB Mucocutaneous candidiasis Oral
NCT04148833 Phase II Phase III Paclitaxel Aortic and coronary atherosclerotic
disease
IV injection
NCT03823040 Phase I Oxiconazole Tinea pedis / Tinea versicolor/Tinea
circinate
SLNs loaded gel for topical
application
CAMB, encochleated amphotericin B; HSP47, Heat Shock Protein; IM, intramuscular; IV, intravenous; OTC, ornithine transcarbamylase; PLK1, polo-like kinase-1;
TTR, Transthyretin.
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Two studies correspond to phase II trials of oral encochleated
amphotericin B (CAMB). Cochleates are constituted by several
layers of continuous lipid bilayers that self-assemble by spiral
wrapping, resulting in relatively rigid cylindrical structures with
the drug.
Among the remaining clinical trials retrieved, two are
undergoing phase III: a cholesterol-rich, protein-free
nanoemulsion of paclitaxel, that resemble low-density
lipoproteins and can be IV administered for the treatment
of atherosclerosis, and lipid NP with patisiran (ALN-TTR02),
a siRNA to treat hereditary transthyretin (TTR) induced
amyloidosis, made with an optimized ionizable cationic lipid,
DLin-MC3-DMA (Kulkarni et al., 2018).
Short interfering RNAs (siRNAs) are 19-23 base pairs double
stranded RNAs that are part of the family of small non-coding
regulatory RNAs (sncRNA). In Fire et al. (1998) described the
gene silencing regulation mechanism of siRNA in Caenorhabditis
elegans, unveiling what later would become a major change
in human therapy approaches. This suppression mechanism,
named RNA interference (RNAi), is a normal mechanism of gene
expression control involving regulation of mRNA translation and
degradation via the binding of short strands of homologous RNA
generated by the Dicer enzyme (Reynolds et al., 2004).
Therefore, siRNA presents as an appealing therapeutic tool to
suppress gene expression, that can be used to silence aberrant
endogenous genes (as in cancer diseases) or to knockdown genes
that are essential to the proliferation of infectious organisms
(Whitehead et al., 2009). However, in order to become a
successful tool for human therapy, siRNA might be administered
as an exogenous RNA product, thus representing a drug delivery
challenge (McManus and Sharp, 2002). Despite the use of cationic
lipids is the natural approach to encapsulate negatively charged
biomolecules like nucleic acids, lipids with a permanent positive
charge tend to form complexes with nucleic acid polymers with
limited or no in vivo utility due to their size (ca. 1 µm of
diameter), instability, positive surface charge, and toxic side
effects (Cullis and Hope, 2017). Ionizable cationic lipids, on
the other hand, allow achieving high loading efficiencies for
RNA/DNA molecules in small (<100 nm) vesicular systems,
with low surface charge (almost neutral) and less toxicity issues
compared with cationic NPs, as discussed in the previous section.
In general, these lipids present an amine group with a
pKa value less than 7, a characteristic that allows them to be
positively charged at low pH values, thus achieving efficient
encapsulation of negatively charged polymers at acidic pH, but
also to exhibit a relatively neutral surface at physiological pH
values (Kulkarni et al., 2018). As mentioned earlier, a recent
research breakthrough on lipid NPs encapsulating siRNA was the
21 base pairs siRNA drug patisiran to treat TTR amyloidosis,
a multisystemic disease causes by misfolded TTR, that affects
nerves, heart, and the gastrointestinal tract (Adams et al., 2017).
Patisiran lipid NPs reduced amyloidogenic protein expression
of the mutated TTR: previous phase II results (NCT01617967)
showed an 80% decrease on TTR levels in serum. The efficacy
results of patisiran constitute a milestone in the field and led to
the approval of the first targeted RNA-lipid NP- based therapy in
August Pastor et al. (2018).
Another kind of RNA therapy is not directed to silence
a given gene but rather to express its product, a therapeutic
protein. Dimitriadis was the first to achieve expression of rabbit
globin on mouse spleen lymphocytes through the delivery of
rabbit reticulocyte 9S mRNA through liposomes (Dimitriadis,
1978). This RNA therapy involves much larger mRNA molecules
than siRNA (1–15 kb, 300-5000 kDA vs. 14 kDa). Therapeutic
approaches may include immunotherapy through mRNA of
antibodies, protein expression to supply the product of a defective
or missing gene, and cellular reprogramming through growth or
transcription factors that modulate cellular metabolism. These
kinds of treatment can be considered improvements over direct
protein administration which face numerous problems like
enzyme degradation or misfolding (Kowalski et al., 2019).
The phase I clinical trial of the biological product named
mRNA-2416, which encodes for OX40L, the ligand of the T
cells co-stimulator tumor necrosis factor receptor superfamily
member 4 (TNFRSF4; OX40). According to the NCI drug
dictionary, expressed on the cancer cells membrane, OX40L
binds to its receptor on T cells to activate a signaling
pathway that leads to an increased cytokine production, thus
inducing proliferation of lymphocytes and subsequent death
of surrounding cancer cells. As in the siRNA systems, this
mRNA is formulated in an ionizable lipid-based NP for
intratumoural injection to patients with relapsed/refractory solid
tumor malignancies or lymphoma.
Another clinical trial (NCT03739931) on lipid nanoparticles
for mRNA delivery to solid tumor malignancies or lymphoma
is currently recruiting patients. In this case, NPs are used for
the intratumoral administration of mRNA-2752, that encodes
OX40L, IL-23 and IL-36G. The co-administration of interleukins
is thought to potentiate the anticancer effect by activating an
inflammatory response at the tumor site (Bauer et al., 2019).
In June 2020, started two phase I clinical trials of ARCT-
810, a mRNA therapy for Ornithine Transcarbamylase (OTC)
deficiency, a genetic disorder produced by a mutation on
the X chromosome. OTC enzyme is involved in the nitrogen
metabolism, and the lack of this protein results in high blood
ammonia levels that might lead to seizure and coma state in
untreated patients. The current treatment is a low protein diet
and ammonia scavenging medication, with future insights on
liver transplantation (Peng et al., 2020). ARCT-810 is formulated
in a novel pH-responsive lipid delivery system named LUNAR R©,
that aims at superseding the lack of native OTC providing a
complete copy of its mRNA, thus restoring enzyme levels to
establish a regular urea cycle. Preclinical data on a murine model
showed full expression of the protein (Perez-Garcia et al., 2019).
In view of the current situation regarding the SARS-CoV-2
pandemic scenario, a recent clinical study respecting a mRNA-
based vaccine has been initiated. The vaccine consists of a lipid
nanoparticle encapsulating mRNA-1273 which encodes for the
full length prefusion stabilized spike protein of the virus (SARS-
CoV-2 spike glycoprotein). After intramuscular administration,
mRNA-1273 translates in the myocytes’ cytoplasm. Spike protein
is released from the cell and captured by macrophages, dendritic
cells, and other immune cells initiating the immune response
(Wang et al., 2020).
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FIGURE 6 | Advantages, current challenges and limitations of working with solid lipid nanoparticles for drug delivery applications.
Leaving aside the CAMB and Oxiconazole formulations, the
described nanovehicles share several common characteristics.
They are non-viral delivery systems derived from classic
liposomes, where the introduction of (permanent or transient)
positively charged lipids that have strong electrostatic
associations with RNA polymers provides larger payloads
of this biomolecules (Cullis and Hope, 2017). Furthermore, most
of them are intended for parenteral administration, with the liver
as target organ. The fact that siRNA therapy is confined to the
liver is a consequence of the tendency of these smaller and more
homogeneous analogs of lipoplexes to accumulate in the liver
(Wittrup and Lieberman, 2015; Kulkarni et al., 2018).
CURRENT CHALLENGES AND
LIMITATIONS OF SOLID LIPID
NANOPARTICLES
The information presented in the previous section reveals that,
aside from cosmetic/dermatological applications (Müller et al.,
2014), there are currently no classical SLN/NLCs in clinical
evaluation stages, so their early entry into the market would not
be expected. Liposomes that have entered the market in recent
years are the result of more than 50 years of research. Similarly,
we could think that there are still years to come before SLN/NLC
enter the pharmaceutical market. A proof that they are still in
their initial stages of research can be seen in the publications
reviewed here, a large percentage of which are technological
(and not disease) focused research, and usually lacking of a
rationale cost/benefit analysis, a characteristic of the initial stages
of any research.
A great number of SLN/NLC reports are based on
experimental drugs with no approved therapeutic indications,
like curcumin, rhein or quercetin, while many others encapsulate
pharmaceutical ingredients for which formulations with good
therapeutic performance are currently available with low
associated costs, such as famotidine, carvedilol, metformin,
ibuprofen, dexamethasone, aliconazole, and many others. But it
is not all bad news. In the case of RNA or DNA therapies, the use
of nanovehicles results essential, since parenterally administered
“naked” nucleic acids fail to reach therapeutic levels in target
cells. They are rapidly degraded in biological fluids (and excreted
by the kidneys) and, if they get to the target tissue, cannot
penetrate into the cells (Cullis and Hope, 2017). Therefore,
whatever the associated cost, it is compensated by the possibility
of having this type of therapies in the market.
Taken altogether, current results on pharmacological
application of SLN/NLC show good perspectives. They have
proven to be safe and versatile drug delivery systems capable
of improving the efficacy and pharmacokinetic profile of the
encapsulated drugs and, as discussed in the previous sections,
many are the therapeutic fields that can be benefited from
the use of these nanocarriers. Large-scale manufacturing
processes, sterilization, tailoring strategies and stability issues
are some of the challenges that need to be overcome before lipid
nanoparticles may become commercially available products, with
approved therapeutic indications (Figure 6).
CONCLUSION AND FINAL REMARKS
In the last decade, SLNs and nanostructured lipid carriers
have attracted much attention as potential drug delivery
(nano)systems. Their major advantage is possibly the use
of biocompatible, environmental-friendly constituents and
preparation methods. Based on their size and biodegradable
Frontiers in Molecular Biosciences | www.frontiersin.org 16 October 2020 | Volume 7 | Article 587997
fmolb-07-587997 October 25, 2020 Time: 16:20 # 17
Scioli Montoto et al. SLN for Drug Delivery
nature, most of the nanocarriers in this category fall within the
low risk class (class I) from the nanotoxicological classification
system suggested by Keck and Müller. It should be noted,
though, that careful clinical and environmental safety assessment
should be performed before advancing these systems to
massive production and commercialization. Development of
standardized procedures to assess potential risks of exposure to
nanomaterials are urgently needed, as well as the correspondent
regulatory framework.
As for other nanosized drug delivery systems, cancer therapy is
the most frequent area of research where SLNs are applied, which
may reflect both the vast levels of funding in the area but also
the suitability of nanocarriers for the delivery of antineoplastic
agents, mainly due to the passive and active targeting posed
by cancerous cells and tissues. Nevertheless, there are many
therapeutic fields that can benefit from the application of lipid
NPs, as discussed for the case of antibiotics and CNS drugs.
Given that the oral administration route is the most
convenient and accepted one for conventional medications, the
fact that nanocarriers (including SLNs) administered through
the oral route are not absorbed extensively, it may seem a
daunting scenario for the advancement of this technology.
However, this may not be true for the particular case of lipid
NPs, since they have demonstrated their ability to increase
the BA of drugs administered orally, a critical point when
it comes to (the increasingly numerous) drugs with very low
solubility in water.
Unfortunately, more time and financial resources are needed
for SLN/NLC to prove its therapeutic value in real scenarios. For
now, the scarcity of SLNs that have reached clinical trials indicates
that at least some years will go by before these technologies land
to the pharmaceutical market.
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Kovačević, A. B., Müller, R. H., Saviæ, S. D., Vuleta, G. M., and Keck, C. M.
(2014). Solid lipid nanoparticles (SLN) stabilized with polyhydroxy surfactants:
preparation, characterization and physical stability investigation. Colloids
Surf. A Physicochem. Eng. Asp. 444, 15–25. doi: 10.1016/J.COLSURFA.2013.
12.023
Kowalski, P. S., Rudra, A., Miao, L., and Anderson, D. G. (2019). Delivering the
messenger: advances in technologies for therapeutic mRNA delivery. Mol. Ther.
27, 710–728. doi: 10.1016/j.ymthe.2019.02.012
Krishna, K. V., Wadhwa, G., Alexander, A., Kanojia, N., Saha, R. N., Kukreti, R.,
et al. (2019). Design and biological evaluation of lipoprotein-based donepezil
nanocarrier for enhanced Brain uptake through oral delivery. ACS Chem.
Neurosci. 10, 4124–4135. doi: 10.1021/acschemneuro.9b00343
Küçüktürkmen, B., and Bozkır, A. (2018). Development and characterization of
cationic solid lipid nanoparticles for co-delivery of pemetrexed and miR-21
antisense oligonucleotide to glioblastoma cells. Drug Dev. Ind. Pharm. 44,
306–315. doi: 10.1080/03639045.2017.1391835
Kulkarni, J. A., Cullis, P. R., and van der Meel, R. (2018). Lipid nanoparticles
enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther. 28,
146–157. doi: 10.1089/nat.2018.0721
Kumar, R., and Sinha, V. R. (2016). Solid lipid nanoparticle: an efficient carrier
for improved ocular permeation of voriconazole. Drug Dev. Ind. Pharm. 42,
1956–1967. doi: 10.1080/03639045.2016.1185437
Kumar, V., Chaudhary, H., and Kamboj, A. (2018). Development and evaluation of
isradipine via rutin-loaded coated solid–lipid nanoparticles. Interv. Med. Appl.
Sci. 10, 236–246. doi: 10.1556/1646.10.2018.45
Kuo, Y.-C., and Lee, C.-H. (2016). Dual targeting of solid lipid nanoparticles grafted
with 83-14 MAb and anti-EGF receptor for malignant brain tumor therapy. Life
Sci. 146, 222–231. doi: 10.1016/j.lfs.2016.01.025
Kuo, Y. C., Rajesh, R., and Hsu, J. P. (2019). Electrophoretic mobility of neuron-like
cells regenerated from iPSCs with induction of retinoic acid- and nerve growth
factor-loaded solid lipid nanoparticles. J. Taiwan Inst. Chem. Eng. 103, 167–176.
doi: 10.1016/j.jtice.2019.07.010
Kuo, Y.-C., and Wang, C.-C. (2014). Cationic solid lipid nanoparticles with
cholesterol-mediated surface layer for transporting saquinavir to the brain.
Biotechnol. Prog. 30, 198–206. doi: 10.1002/btpr.1834
Kurakula, M., Ahmed, O. A. A., Fahmy, U. A., and Ahmed, T. A. (2016).
Solid lipid nanoparticles for transdermal delivery of avanafil: optimization,
formulation, in-vitro and ex-vivo studies. J. Liposome Res. 26, 288–296. doi:
10.3109/08982104.2015.1117490
Lahkar, S., and Kumar Das, M. (2018). Surface modified kokum butter lipid
nanoparticles for the brain targeted delivery of nevirapine. J. Microencapsul. 35,
680–694. doi: 10.1080/02652048.2019.1573857
le Chatelier, H. (1919). Crystalloids against colloids in the theory of cements. Trans.
Faraday Soc. 14, 8–11. doi: 10.1039/tf9191400008
Leite, E. R., and Ribeiro, C. (2012). “Basic principles: thermodynamics and colloidal
chemistry,” in Crystallization and Growth of Colloidal Nanocrystals, eds E. R.
Leite and C. Ribeiro (New York, NY: Springer), 7–17. doi: 10.1007/978-1-4614-
1308-0_2
Li, Y., Wu, M., Zhang, N., Tang, C., Jiang, P., Liu, X., et al. (2018). Mechanisms
of enhanced antiglioma efficacy of polysorbate 80-modified paclitaxel-loaded
PLGA nanoparticles by focused ultrasound. J. Cell. Mol. Med. 22, 4171–4182.
doi: 10.1111/jcmm.13695
Lima, T., Bernfur, K., Vilanova, M., and Cedervall, T. (2020). Understanding the
lipid and protein corona formation on different sized polymeric nanoparticles.
Sci. Rep. 10:1129. doi: 10.1038/s41598-020-57943-6
Liu, J.-L., Li, J., Zhang, L.-Y., Zhang, P.-L., Zhou, J.-L., and Liu, B. (2017).
Preparation of N, N, N-trimethyl chitosan-functionalized retinoic acid-loaded
lipid nanoparticles for enhanced drug delivery to glioblastoma. Trop. J. Pharm.
Res. 16, 1765–1772. doi: 10.4314/tjpr.v16i8.3
Luo, Y., Teng, Z., Li, Y., and Wang, Q. (2015). Solid lipid nanoparticles for oral drug
delivery: chitosan coating improves stability, controlled delivery, mucoadhesion
and cellular uptake. Carbohydr. Polym. 122, 221–229. doi: 10.1016/J.CARBPOL.
2014.12.084
Ma, Y., He, H., Xia, F., Li, Y., Lu, Y., Chen, D., et al. (2017). In vivo fate of lipid-
silybin conjugate nanoparticles: implications on enhanced oral bioavailability.
Nanomedicine 13, 2643–2654. doi: 10.1016/j.nano.2017.07.014
Ma, Z., Wang, N., He, H., and Tang, X. (2019). Pharmaceutical strategies of
improving oral systemic bioavailability of curcumin for clinical application.
J. Control. Release 316, 359–380. doi: 10.1016/j.jconrel.2019.10.053
Maaßen, S., Schwarz, C., Mehnert, W., Lucks, J. S., Yunis-Specht, F., Muller, B. W.,
et al. (1993). Comparison of cytotoxicity between polyester nanoparticles and
solid lipid nanoparticles (SLN). Proc. Int. Symp. Control. Rel. Bioact. Mater. 20,
490–491.
Mahmoud, R. A., Hussein, A. K., Nasef, G. A., and Mansour, H. F.
(2020). Oxiconazole nitrate solid lipid nanoparticles: formulation, in-vitro
characterization and clinical assessment of an analogous loaded carbopol gel.
Drug Dev. Ind. Pharm. 46, 706–716. doi: 10.1080/03639045.2020.1752707
Maisel, K., Ensign, L., Reddy, M., Cone, R., and Hanes, J. (2015). Effect of
surface chemistry on nanoparticle interaction with gastrointestinal mucus and
distribution in the gastrointestinal tract following oral and rectal administration
in the mouse. J. Control. Release 197, 48–57. doi: 10.1016/J.JCONREL.2014.
10.026
Maretti, E., Costantino, L., Rustichelli, C., Leo, E., Croce, M. A., Buttini, F.,
et al. (2017). Surface engineering of Solid Lipid Nanoparticle assemblies by
Frontiers in Molecular Biosciences | www.frontiersin.org 20 October 2020 | Volume 7 | Article 587997
fmolb-07-587997 October 25, 2020 Time: 16:20 # 21
Scioli Montoto et al. SLN for Drug Delivery
methyl α-D-mannopyranoside for the active targeting to macrophages in anti-
tuberculosis inhalation therapy. Int. J. Pharm. 528, 440–451. doi: 10.1016/j.
ijpharm.2017.06.045
Martínez-Jothar, L., Barendrecht, A. D., de Graaff, A. M., Oliveira, S., van
Nostrum, C. F., Schiffelers, R. M., et al. (2020). Endothelial cell targeting by
crgd-functionalized polymeric nanoparticles under static and flow conditions.
Nanomaterials 10:1353. doi: 10.3390/nano10071353
Martins, S., Sarmento, B., Ferreira, D. C., and Souto, E. B. (2007). Lipid-based
colloidal carriers for peptide and protein delivery–liposomes versus lipid
nanoparticles. Int. J. Nanomed. 2, 595–607.
Mazuryk, J., Deptuła, T., Polchi, A., Gapiński, J., Giovagnoli, S., Magini, A., et al.
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